Rigel Pharmaceuticals - Best Pharma Stocks of 2007
Company: Rigel Pharmaceuticals
Starting stock price: $11.89
Ending stock price: $25.39
Percent Change: 113.54%
Details: Rigel has a number of drug candidates in its pipeline. R788 is in Phase II trials for rheumatoid arthritis, ITP and B-cell lymphoma. It's also partnering with Merck Serono on the Phase II compound R763 for solid tumors and leukemia. Additionally, Rigel and Pfizer are developing R343 for asthma.
More News:
Merck Serono exercises option to Rigel's R763. Report
Serono seals oncology drug pact with Rigel. Report
More stories about Rigel Pharmaceuticals
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment